IVC Filters May Prevent Fatal Pulmonary Embolism in Musculoskeletal Tumor Surgery

Abstract

Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

Incidence, Diagnosis, and Risk Factors of Venous Thromboembolism after Surgery for Malignant Bone and Soft Tissue Tumor of Lower Extremity

“…There are few reports about postoperative VTE development in malignant bone and soft tissue tumors [10][11][12][13][14][15][16][17][18][19][20][21]. As large studies occasionally include patients receiving anticoagulant therapy or localization of the upper extremity, we cannot compare the postoperative VTE incidences and risk factors equally.…”

“…A further study will be necessary regarding the safety of anticoagulant therapy in malignant bone and soft tissue tumors in the future. This is because most patients who underwent limb salvage surgery did not receive anticoagulant therapy during the early postoperative period due to concerns of bleeding and wound complications [13].…”

Incidence and Risk Factors for Pulmonary Embolism After Primary Musculoskeletal Tumor Surgery

“…The cited articles studied PE and VTE, unlike our study. The reported incidence of PE after musculoskeletal tumor surgery in earlier studies has varied widely, from 0.6% to 11% [2,13,16,27]. This wide range presumably results from heterogeneity among study subjects, small sample sizes, and variations in surveying for PE and in prophylaxis.…”

“…It generally is recognized that patients with malignant disease are at increased risk of PE [3,7,12,13,26,27]. This increased risk has been observed in many different types and stages of malignancies, but the PE risk in patients with musculoskeletal sarcoma remains unclear.…”

“…However, there is limited information available regarding the incidence, risk factors, and optimal prophylaxis for VTE in orthopaedic oncology patients, presumably because of the rarity of these diseases. The reported incidence of PE in these patients is between 0.6% and 11% [2,13,16,27], but these data were based on small and heterogeneous patient cohorts at a single referral center. The wide range of reported incidences may result from the inclusion of patients with metastatic bone tumors who may have a higher risk of PE.…”